Dark Horse Consulting Launches Initiative for Certification of Manufacturing Capabilities
October 07, 2024 07:58 ET
|
Dark Horse Consulting Group
Dark Horse Consulting Group, leading cell and gene therapy consultancy, today unveils the Initiative for Certification of Manufacturing Capabilities: ICMC™
Dark Horse Consulting Group Acquires BioTechLogic, Inc.
October 03, 2024 11:18 ET
|
Dark Horse Consulting Group
Dark Horse Consulting Group, the global leader in cell and gene therapy consulting, is delighted to announce the acquisition of BioTechLogic, Inc.
Kriya Appoints Katherine Eade as Chief Legal Officer
June 18, 2024 09:05 ET
|
Kriya Therapeutics, Inc.
PALO ALTO, Calif., and RESEARCH TRIANGLE PARK, N.C., June 18, 2024 (GLOBE NEWSWIRE) -- Kriya Therapeutics, Inc. ("Kriya"), a biopharmaceutical company developing gene therapies to address common...
Kriya Announces Three Presentations at the 2024 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
May 02, 2024 09:05 ET
|
Kriya Therapeutics, Inc.
– Kriya is developing KRIYA-825 as a potential one-time gene therapy expressing a fusion protein inhibiting the activity of complement C3 and C5 for the treatment of Geographic Atrophy – PALO...
Kriya Announces Six Presentations at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting 2024
April 22, 2024 16:30 ET
|
Kriya Therapeutics, Inc.
– Current pipeline of gene therapies for common diseases spans three major therapeutics areas: ophthalmology, metabolic disease and neurology – – Company to host symposium on “Advancing Gene...
ClearPoint Neuro Congratulates its Partner PTC Therapeutics on Completion of Biologics License Application Submission to FDA for Upstaza™ as a Treatment for AADC Deficiency
March 19, 2024 08:07 ET
|
ClearPoint Neuro, Inc.
ClearPoint Neuro's partner's completed BLA Submission for Upstaza™ would be first disease-modifying treatment for AADC Deficiency in the US.
Muscular Dystrophy Association Announces Recipient of 2024 MDA Legacy Award for Achievement in Research, is Jeffrey Chamberlain, Ph.D., Leading Professor in Gene Therapy
January 30, 2024 09:59 ET
|
Muscular Dystrophy Association
New York, Jan. 30, 2024 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) today announced Jeffrey Chamberlain, Ph.D., a leading professor in gene therapy focused on Duchenne muscular...
Kriya Provides Update on Pipeline Progress Ahead of Company Presentation at 42nd Annual J.P. Morgan Healthcare Conference
January 08, 2024 09:00 ET
|
Kriya Therapeutics, Inc.
– Kriya anticipates up to 5 programs to enter clinic by the end of 2025 – – Current pipeline of gene therapies for common diseases spans three major therapeutics areas: ophthalmology, metabolic...
Kriya Announces Gene Therapy Program for Thyroid Eye Disease
January 05, 2024 09:00 ET
|
Kriya Therapeutics, Inc.
– KRIYA-586 is designed to be a one-time treatment delivered by focal peribulbar injection, that encodes an antibody blocking the Insulin-Like Growth Factor 1 Receptor (IGF-1R), a clinically validated...
Dark Horse Consulting Group Announces Launching of DHC Asia Pacific, Hiring of John Ng as General Manager
November 13, 2023 16:20 ET
|
Dark Horse Consulting Group
Dark Horse Consulting Group Announces Launching of DHC Asia Pacific, Hiring of John Ng as General Manager